Copper Peptides for Hair: What the Evidence Shows

Copper peptides have become one of the most searched hair-growth ingredients, mostly on the strength of GHK-Cu's reputation in skincare. The short answer: the lab and animal data are genuinely interesting, but there is no published placebo-controlled trial showing that a copper peptide on its own regrows hair in people. Every human result that sounds impressive comes bundled with something else — usually a drug that already works.

What GHK-Cu Actually Is

GHK is a three-amino-acid peptide — glycyl-L-histidyl-L-lysine — present in human plasma, saliva and urine, and its levels decline with age. It binds copper readily, and the resulting complex, GHK-Cu, is the molecule most people mean by "copper peptides." On ingredient labels it usually appears as copper tripeptide-1.

Two distinctions matter when reading the research and the marketing:

• GHK-Cu vs. AHK-Cu. AHK-Cu (L-alanyl-L-histidyl-L-lysine-copper) is a different tripeptide-copper complex. The best-known lab study on human hair follicles actually tested AHK-Cu, not GHK-Cu — yet it is routinely cited as evidence for GHK-Cu products.
• Copper-bound vs. copper-free GHK. GHK is also sold and studied without copper. The only randomized, placebo-controlled hair trial we found used copper-free GHK chemically joined to another compound.

Most GHK-Cu research concerns wound healing and facial skin, not hair. A 2026 systematic review in Aesthetic Surgery Journal included 20 studies of GHK-Cu as a standalone aesthetic intervention — 18 preclinical and just 2 randomized trials — and concluded that the field is limited by "a limited number of well-designed clinical trials."

The Hair Evidence, Study by Study

Here is every study we could verify on PubMed that tested a copper peptide (or GHK) on hair, ordered from lab to human.

Read down the table and a pattern is obvious. The studies that isolate a copper peptide are in a dish or in rodents. The studies in people either used copper-free GHK bonded to another compound, or used copper peptides as one ingredient among drugs that already work.

The One Placebo-Controlled Trial

The closest thing to a real test is Lee and colleagues' 2016 trial in Annals of Dermatology. Forty-five men with male pattern hair loss sprayed a compound called ALAVAX — 5-aminolevulinic acid (5-ALA) chemically linked to GHK — at 100 mg/ml or 50 mg/ml, or a placebo, once daily for six months.

Hair counts rose by 52.6 and 71.5 hairs in the two active groups versus 9.6 on placebo, and the lower-dose group's ratio of change in hair count was significantly better than placebo. There was no difference in hair length or thickness, and no adverse events were reported.

That is a genuine signal, but it is not evidence for a copper peptide serum. The full text describes synthesizing GHK and linking it to 5-ALA with no copper step, citing earlier work suggesting copper-free GHK can mimic GHK-Cu. A GHK-Cu product on a shelf is a different molecule. The trial is also small — the methods randomized 15, 14 and 14 men — and has not been replicated.

The Combination Studies

The larger and more dramatic human reports all share one feature: copper peptides were mixed with something stronger. The seven-patient tattooing series used minoxidil and dutasteride; the 18,918-patient clinic series used oral finasteride and oral and topical minoxidil; the 1,000-patient injection study used several growth factors. The 2024 dandruff study paired a copper tripeptide-1 serum with a hydroxy acid scrub, ran for 15 days, and was co-authored by an employee of the manufacturer. Kuceki and colleagues list the lack of a control arm as a limitation themselves.

None of these studies can tell you what the copper peptide did. Minoxidil, dutasteride and finasteride regrow hair on their own, so improvement in these patients is exactly what you would expect even if the copper peptide contributed nothing.

Mechanism Claims vs. Evidence

Marketing for copper peptide hair serums leans heavily on mechanism. Some of those mechanisms are real lab findings; none has been shown to translate into regrowth on a human scalp.

• "Stimulates the dermal papilla and enlarges follicles." Supported in the lab (AHK-Cu, human follicles) and in rodents (a copper-binding peptide in rats). Not shown in a controlled human trial of GHK-Cu.
• "Increases blood vessel growth factors." Pyo's paper describes the tripeptide-copper complex raising vascular endothelial growth factor production by fibroblasts. That is a cell-culture finding.
• "Blocks DHT." We found no PubMed study showing GHK-Cu inhibits 5-alpha-reductase or lowers DHT. Treat this claim as unsupported.
• "Resets thousands of genes" and "improves hair transplant success." These come from reviews written by Loren Pickart, who first isolated the peptide, with Skin Biology listed as the author affiliation. A 2026 systematic review notes that about 35% of the GHK-Cu primary literature includes Pickart or a Skin Biology colleague as an author, that Pickart "held commercial interests in the field for decades," and that this concentration "limits the independence of the evidence base." We could not find a controlled hair-transplant trial on PubMed to back the transplant claim.

Penetration is a fair question too. An in vitro study using human skin in diffusion cells found copper from a 0.68% copper tripeptide solution did permeate dermatomed skin. That suggests a topical can reach the skin's deeper layers in a lab setup; it does not establish that a given serum delivers enough to a follicle to change hair growth.

Safety and Irritation

Topical copper peptides have a reassuring but thin safety record for hair use specifically. The 2016 placebo-controlled trial reported no adverse events, the tattooing series reported no scarring or infection, and the injection study described treatment as well tolerated. None of these was designed or large enough to detect uncommon reactions.

Practical points:

• Patch test first. Serums often contain fragrance, essential oils or botanical extracts alongside the peptide, and any of these can irritate a scalp. Apply a small amount behind the ear or on the inner arm for a day before using it on your scalp.
• Stop if your scalp reacts. Redness, burning or new flaking is a reason to stop, not to push through.
• Injections are a different category. "GHK-Cu peptide" vials sold online or through some clinics are not an approved hair-loss treatment. The FDA lists GHK-Cu for injectable routes among bulk drug substances for compounding that may present significant safety risks, citing possible immunogenicity from aggregation and peptide-related impurities and noting "limited data in humans to inform safety-related considerations."

How Copper Peptides Compare to Proven Treatments

The gap here is not subtle. In a 48-week randomized, placebo-controlled trial of 393 men, 5% topical minoxidil produced significantly more regrowth than 2% minoxidil and placebo. In two one-year placebo-controlled trials of 1,553 men, finasteride 1 mg increased hair counts at one and two years, while men on placebo kept losing hair.

Copper peptides have nothing at that level: no placebo-controlled trial of GHK-Cu alone, no head-to-head comparison against minoxidil, and no long-term data. "Copper peptides vs. minoxidil" is not a real contest on current evidence.

If you have pattern hair loss, start with the treatments that have earned it — see our best minoxidil guide and finasteride guide, or the finasteride vs. minoxidil comparison. Copper peptides are, at best, an optional add-on.

For context among the other natural options: rosemary oil has a randomized trial against 2% minoxidil, and spermidine and ceramides have placebo-controlled supplement trials. A topical copper peptide currently has less direct human hair evidence than either.

How to Judge a Copper Peptide Product

If you still want to try one, these questions separate a reasonable product from an overpromising one:

1. Does it say which peptide? "Copper tripeptide-1" is GHK-Cu. "Copper peptides" alone, or a long list of trademarked "peptide complexes," tells you little.
2. Does it claim to regrow hair or block DHT? No copper peptide product has the evidence for either. A brand that says so is overclaiming.
3. Is the "clinically proven" claim about this product? Most cite the AHK-Cu lab study, rodent work or the 5-ALA–GHK trial — none of which tested the serum you are looking at.
4. What else is in it? If the formula includes minoxidil, that is doing the heavy lifting. If it includes several essential oils or fragrance, irritation risk goes up.
5. Is it a topical? Injectable or "research-use" GHK-Cu is a separate risk discussion, covered above.

For a broader look at what scalp serums can and cannot do, see our guide to scalp serums for hair growth.

The Bottom Line

GHK-Cu is a real, well-studied molecule with credible wound-healing and skin data, and the early hair findings — follicle elongation in a dish, follicle enlargement in rodents — explain why people are interested. But the human hair evidence is thin. The one placebo-controlled trial used copper-free GHK bonded to another compound, and every other human report mixed copper peptides with drugs that already regrow hair.

Do copper peptides regrow hair? Nobody has shown that they do on their own. A copper peptide serum is a low-risk cosmetic you can add if you like the idea — not a replacement for minoxidil or finasteride, and not a reason to delay treatment that works.

Sources

1. Pyo HK, Yoo HG, Won CH, et al. The effect of tripeptide-copper complex on human hair growth in vitro. Archives of Pharmacal Research. 2007;30(7):834-839. PMID: 17703734.
2. Trachy RE, Fors TD, Pickart L, Uno H. The hair follicle-stimulating properties of peptide copper complexes. Results in C3H mice. Annals of the New York Academy of Sciences. 1991;642:468-469. PMID: 1809108.
3. Uno H, Kurata S. Chemical agents and peptides affect hair growth. Journal of Investigative Dermatology. 1993;101(1 Suppl):143S-147S. PMID: 8326148.
4. Lee WJ, Sim HB, Jang YH, et al. Efficacy of a complex of 5-aminolevulinic acid and glycyl-histidyl-lysine peptide on hair growth. Annals of Dermatology. 2016;28(4):438-443. PMID: 27489425.
5. Kapoor R, Shome D. Intradermal injections of a hair growth factor formulation for enhancement of human hair regrowth: safety and efficacy evaluation in a first-in-man pilot clinical study. Journal of Cosmetic and Laser Therapy. 2018;20(6):369-379. PMID: 29482481.
6. Bertin ACJ, Vilarinho A, Junqueira ALA. Fractional non-ablative laser-assisted drug delivery leads to improvement in male and female pattern hair loss. Journal of Cosmetic and Laser Therapy. 2018;20(7-8):391-394. PMID: 29452017.
7. Tanaka Y, Aso T, Ono J, Hosoi R, Kaneko T. Androgenetic alopecia treatment in Asian men. Journal of Clinical and Aesthetic Dermatology. 2018;11(7):32-35. PMID: 30057663.
8. Kuceki G, Coppinger AJ, Ragi SD, et al. Enhanced hair regrowth with five monthly sessions of minoxidil-dutasteride-copper peptides tattooing for androgenetic alopecia assessed by artificial intelligence and blinded evaluators. JAAD International. 2025;20:38-40. PMID: 40225275.
9. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. PMID: 18644225.
10. Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. 2015;2015:648108. PMID: 26236730.
11. Najafi N, Maatouk H, Vardanyan KG, Vartanian KB, Agrawal DK. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery: a case for expanded clinical trials. Archives of Internal Medicine Research. 2026;9(3):269-293. PMID: 42787770.
12. Mokhtar J, Mohamad B, Haddad J, et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal. 2026. PMID: 42619529.
13. Hostynek JJ, Dreher F, Maibach HI. Human skin penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research. 2011;60(1):79-86. PMID: 20721598.
14. Patel MN, Patel N, Merja A, Patnaik S. An assessment of the safety, efficacy, and tolerability of a novel scalp treatment regimen combining a hydroxy acid-based scrub and copper tripeptide serum in the management of seborrheic dermatitis in adults. Cureus. 2024;16(9):e70108. PMID: 39449909.
15. Olsen EA, Dunlap FE, Funicella T, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Journal of the American Academy of Dermatology. 2002;47(3):377-385. PMID: 12196747.
16. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride in the treatment of men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1998;39(4 Pt 1):578-589. PMID: 9777765.
17. US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Accessed October 2026.